title: Target promiscuity and physicochemical properties contribute to pharmacologically induced ER-stress.
abstract: In vivo toxicity of drug candidates remains a major problem in the pharmaceutical industry, and is a significant cause of late stage attrition. As a consequence predictive in vitro assays are developed and put in place early in the discovery pipeline to aid compound selection. Endoplasmic reticulum stress (ER-stress) has been implicated in many disease states, as well as compound-induced organ toxicities. We explored the role of ER-stress as a general mechanism of toxicity by utilizing a high-throughput in vitro assay to screen 316 chemically diverse Pfizer proprietary compounds with known in vivo toxicity outcome for nuclear accumulation of spliced x-box binding protein 1 (XBP1s), a key transcription factor of the unfolded protein response (UPR). We examined the correlation between physicochemical properties, such as molecular weight, pKA, lipophilicity, topological polar surface area, and passive permeability, as well as target promiscuity, between XBP1s hits and non-hits and found that lipophilicity, target promiscuity and low passive permeability significantly contributed to ER-stress. In addition, we have shown that compounds which cause ER-stress in the form of XBP1s activation at concentrations below 40 μM have a more than four times greater chance of causing in vivo toxicity at 10 μM plasma exposure.
authors.affiliation: Compound Safety Prediction, Worldwide Medicinal Chemistry, Pfizer Inc, Groton, CT 06340, United States.
authors.forename: E
authors.initials: E
authors.lastname: Koslov-Davino
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: T
authors.initials: T
authors.lastname: Schroeter
mesh_terms: D045744:Cell Line, Tumor; D004268:DNA-Binding Proteins / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D064420:Drug-Related Side Effects and Adverse Reactions; D059865:Endoplasmic Reticulum Stress; D057166:High-Throughput Screening Assays; D006801:Humans; D008970:Molecular Weight; D004364:Pharmaceutical Preparations / Q000737:chemistry; D000071701:Regulatory Factor X Transcription Factors; D013499:Surface Properties; D014157:Transcription Factors / Q000378:metabolism; D000071717:X-Box Binding Protein 1
chemical_list: D004268:DNA-Binding Proteins; D004364:Pharmaceutical Preparations; D000071701:Regulatory Factor X Transcription Factors; D014157:Transcription Factors; D000071717:X-Box Binding Protein 1; C000605543:XBP1 protein, human